Premium
Combination photodynamic therapy + sphingolipid analog LCL85 leads to autophagy, defective apoptosis and long‐term sensitization
Author(s) -
Separovic Duska,
Joseph Nicholas,
Breen Paul,
Saad Ziad H.,
Bielawska Alicja
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.852.13
Subject(s) - autophagy , photodynamic therapy , sensitization , ceramide , apoptosis , sphingolipid , programmed cell death , cancer research , viability assay , clonogenic assay , chemistry , microbiology and biotechnology , medicine , biology , immunology , biochemistry , organic chemistry
Two anticancer agents, LCL85 and photodynamic therapy (PDT) were combined to test whether the combination PDT/LCL85 evokes changes in the sphingolipid (SL) profile and promotes cell death. Short‐term exposure to PDT/LCL85 led to enhanced levels of C18‐, C20‐, and C20:1‐ceramide, and C18‐DHceramide, enhanced autophagy and defective apoptosis, without affecting cell viability. In contrast, long‐term clonogenic survival was reduced not only after PDT or LCL85, but even more after PDT/LCL85, supporting translational potential of PDT/LCL85.